The disclosure relates to compositions and methods for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Use of gemcitabine, including in self-emulsifying orally administered dosage forms for these purposes is described. Gemcitabine is orally administered in a metronomic manner, which involves repeatedly administering a therapeutic amount of gemcitabine, being a fraction of the maximum tolerated dose, over an extended period of time, preferably on a non-interrupted schedule of weeks, months, or indefinitely.
